西亚试剂:Amgen ($AMGN) has taken a big stride toward gaining regulat

发布时间：2026-02-10

Amgen ($AMGN) has taken a big stride toward gaining regulatory approval for its biosimilar of Humira, AbbVie's ($ABBV) megablockbuster anti-inflammatory. The Big Biotech reports today that its knockoff of Humira--dubbed ABP 501--hit its marks on equivalency for efficacy and safety for treating plaque psoriasis.

Amgen didn't spell out the actual data, but it declared victory in the first of two planned Phase III studies comparing its follow-on drug with Humira (adalimumab), which made $10.7 billion last year for use against a range of diseases like psoriasis, rheumatoid arthritis, Crohn's disease, ulcerative colitis and more. Humira currently accounts for 60% of AbbVie's revenue and loses patent protection in the U.S. in 2016 and in Europe in 2018.

The primary endpoint of the Phase III was the Psoriasis Area and Severity Index, or PASI, percent improvement from baseline to week 16 of treatment.

Amgen was in the first wave of developers to stake out a plan to manufacture biosimilars, and Humira is a prime target in the field. Most analysts expect these biosimilars will carve 20% to 30% off the price of the branded biologic, a hefty discount but nothing close to the huge price cuts associated with traditional generics.

Amgen is also likely to face a host of newly approved biologics with a better efficacy and safety profile for psoriasis, including one of its own experimental therapies. Novartis ($NVS), Celgene ($CELG) and a partnership of AstraZeneca ($AZN) and Amgen for brodalumab have all been hard at work. And Amgen is not alone in developing biosimilars to Humira. Sandoz started its Phase III program for its knockoff at the end of last year. And Coherus, which is targeting niche markets, also has one in the pipeline.

"Results from Amgen's biosimilar Phase III plaque psoriasis study met the primary endpoint for efficacy and showed comparable safety and immunogenicity to adalimumab, which further demonstrates the company's commitment to provide patients with access to high-quality medicines," said Dr. Sean Harper, the head of R&D at Amgen. "We look forward to continuing to leverage our experience and expertise in biotechnology to bring biosimilars to patients."

• 以上资料由西亚试剂：http://www.xiyashiji.com/ 提供此产品的详细信息如密度,含量,分子式,分子量等均可在西亚官网查询   
• 相关产品如汞乙酸汞氯化汞氧化汞碘化汞硫酸汞硝酸汞溴化汞硝酸亚汞氯化亚汞乙酸苯汞碘化汞钾硫氰酸汞氯化氨基汞三氯生三氯氧磷三氯乙烯水合氯醛三氯化磷三氯化钌三氯化钛三氯化铱三氯化铑三氯硫磷三氯乙烷三氯甲烷三氯卡班TCC1,3,5-三氯苯1,2,4-三氯苯1,2,3-三氯苯无水氯化铝三氯乙酸酐三氯乙酸钠碘甲烷二碘甲烷三碘甲烷 三氟碘甲烷硫酸二甲酯氯磺酸苯硫酚苯硫酚钠3-氨基苯硫酚2,6-二氯苯硫酚2,4-二氯苯硫酚2,5-二氯苯硫酚2-甲氧基苯硫酚2-氯乙醇氯甲基甲醚 等均有销售.欢迎订购

上一篇：西亚试剂：2-三氟甲基苯甲醇
下一篇：西亚试剂：科学家发现人类走路姿势与指纹一样可作识别特征